Press Releases

Email Alerts

Nov 6, 2018

Biostage awarded $1.1 million Phase II NIH SBIR Fast-Track grant to develop Cellspan™ Esophageal Implant (CEI) as a novel treatment for pediatric esophageal atresia

- These nondilutive funds support development, testing and IND submission of the Company's pediatric esophageal implant candidate

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced it has...
Nov 2, 2018

Biostage to Host Conference Call to Discuss Third Quarter 2018 Financial Results and Operations

- Conference Call with Live Audio Webcast on Thursday November 8th at 9:30 AM ET -

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, announced today that it...
Aug 14, 2018

Biostage Reports 2018 Second Quarter Financial Results

- Company making steady progress on mid-term goals

Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and...
Aug 9, 2018

Biostage to Host Conference Call to Discuss Second Quarter 2018 Financial Results and Operations

- Conference Call with Live Audio Webcast on Tuesday, August 14th at 9:00 AM ET -

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, announced today that it...
May 31, 2018

Biostage Closes $3.6 Million Private Placement at a price of $3.60 per share

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced that the...

Show per page